News
Rolling its valuation models to year‑end 2026, Wolfe raised its fair‑value range to $53–$112 a share, compared with Monday’s $69 close, and said the risk‑reward now tilts positive even though downside ...
Symvess, described as an acellular tissue engineered vessel, received FDA approval for extremity vascular trauma indication in December 2024. The product is part of Humacyte’s commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results